logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
10/12/2022 3:05:54 AM Sangamo Therapeutics Announces Updated Phase 1/2 Data In Fabry Disease Showing Well Tolerated Across Four Dose Cohorts
9/23/2022 7:12:58 AM Wedbush Reiterates Sangamo Biosciences Inc (SGMO) At Neutral With $5 Price Target
8/30/2022 6:08:04 AM Sangamo Therapeutics Announces Updated Results From Phase 1/2 STAAR Study Of Isaralgagene Civaparvovec For Fabry Diseas
7/21/2022 8:25:05 AM European Orphan Medicinal Product Designation Granted To Sangamo CAR-Treg Cell Therapy For Solid Organ Transplantation
3/29/2022 8:08:47 AM Sangamo Reports Dosing Of First Patient In Phase 1/2 Study Of CAR-Treg Cell Therapy TX200 In Kidney Transplantation
1/6/2022 8:33:31 AM Sangamo Reports Transition Of SAR445136 Sickle Cell Disease Program From Sanofi To Sangamo
12/12/2021 9:05:25 AM Sangamo Therapeutics Reports Updated Preliminary Proof-of-concept Data From Phase 1/2 PRECIZN-1 Study Of SAR44513
11/4/2021 9:14:20 AM Sangamo Therapeutics Q3 Attributable Loss $47.7 Mln Or $0.33/shr Vs. Loss $1.6 Mln Or $0.01/shr Prior Year
11/4/2021 8:17:26 AM Sangamo : Phase 1/2 Data Shows Tolerability And Sustained Elevated -Gal A Enzyme Activity In Patients With Fabry Disease
5/24/2021 4:28:34 PM Sangamo Therapeutics Appoints Prathyusha Duraibabu As CFO
8/12/2019 7:42:55 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) FY20 Rev. Estimate To 55.1 M From 74.2 M
8/12/2019 7:42:39 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 20 Rev. Estimate To 9.5 M From 14.2 M
8/12/2019 7:42:29 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q3 20 Rev. Estimate To 9.2 M From 14.0 M
8/12/2019 7:42:16 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q2 20 Rev. Estimate To 9.2 M From 14.0 M
8/12/2019 7:41:57 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q1 20 Rev. Estimate To 27.2 M From 32.0 M
8/12/2019 7:41:29 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) FY19 Rev. Estimate To 61.3 M From 100 M
8/12/2019 7:38:44 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q4 19 Rev. Estimate To 18.9 M From 32.2 M
8/12/2019 7:37:51 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 19 Rev. Estimate To 16.9 M From 30.2 M
8/12/2019 7:36:25 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) FY20 Estimate To -1.34 From -1.17